GlobeNewswire

2024-11-13 23:00

DEBx Medical Secures Expanded Investment from TVM Capital Healthcare

DEBx Medical is poised for accelerated growth in chronic wound solutions, bolstered by the second round of investment by TVM Capital Healthcare.

AMSTERDAM and DUBAI, United Arab Emirates, Nov. 13, 2024 (GLOBE NEWSWIRE) -- DEBx Medical, an Amsterdam-based pioneering innovator in the field of advanced wound care, announces the successful completion of its second capital investment round led by TVM Capital Healthcare. The funding will accelerate DEBx Medical’s global expansion into major markets around the world.

The investment follows a successful initial round of funding and reflects growing confidence in DEBx Medical’s innovative approach to chronic wound management, specifically through its breakthrough solution, DEBRICHEM®, a topical desiccating agent used to eradicate biofilm and infection from chronic wounds.

Global Market Expansion to Transform Chronic Wound Care

This second investment round will support the company’s strategy to expand into the highly regulated and competitive markets, further supporting DEBx Medical’s mission to transform the management of chronic wounds and improve patient outcomes.

Chronic wounds impose a considerable burden on healthcare systems world over, not just due to their prevalence but also due to the associated costs, complications, and impacts on patients' quality of life.

DEBRICHEM® offers an unparalleled solution completely eradicating biofilm and infection from chronic wounds, and with CE and ISO certifications obtained, the company has successfully treated thousands of patients since its market introduction.

Investor Perspective

“This new round of funding from TVM Capital Healthcare will accelerate the commercialization of DEBRICHEM® worldwide and enable DEBx Medical to reach more patients and alleviate the suffering caused by non-healing wounds,” commented Tristan de Boysson, Managing Partner of TVM Capital Healthcare. “We are also recommitting to the TVM Healthcare Afiyah Fund strategy to bring innovative solutions to the MENA region, particularly, in the Kingdom of Saudi Arabia, and look forward to working with this impressive team to achieve those objectives.”

TVM Capital Healthcare’s renewed investment will further enable DEBx Medical to expand its commercialization efforts.

“We are excited to take this important step in DEBx Medical’s journey toward global expansion,” said Bert Quint, CEO of DEBx Medical. “This round of funding will allow us to enter key markets around the world, where the burden of chronic wounds remains significant. Our investors’ support is a strong validation of our product’s potential to transform wound care practices worldwide.”

Driving Innovation in Wound Care

DEBRICHEM® has already made a significant impact in Europe and parts of the MENA region, including KSA, offering healthcare professionals a powerful solution to treat chronic wounds. The product has shown remarkable results in helping restart the healing process in wounds where biofilm and infection have been a barrier.

A Media Snippet accompanying this announcement is available by clicking on this link.

Future Growth and Development

In addition to expanding its geographic reach, DEBx Medical plans to continue advancing its research and development efforts to introduce new solutions in wound care. The company’s focus on clinical data and evidence-based medicine will remain a driving force as it seeks to broaden its product portfolio and address unmet needs in chronic wound treatment.

About DEBx Medical

DEBx Medical is dedicated to transforming wound care through innovative, scientifically driven solutions. Founded in 2019, the company’s mission is to improve the lives of patients with chronic wounds by providing healthcare professionals with groundbreaking tools to treat complex wounds effectively. DEBRICHEM®, the company’s flagship product, is a topical desiccating agent that eliminates biofilm and infection, promoting faster and more efficient wound healing. For more information, visit: DEBx Medical - Innovating The Future of Wound Care (debx-medical.com)

About TVM Capital Healthcare

TVM Capital Healthcare is a global healthcare private equity firm specializing in emerging markets. Headquartered in Dubai and Singapore, with offices in Riyadh, Boston, Munich, and Ho Chi Minh City, the firm invests expansion and growth capital in healthcare companies to improve local access to quality and affordable care, as well as local sources of medical products in the pharma, medical device, and diagnostics sectors. Investment and operating partners, as well as a strong group of regional and international senior advisors, have long-standing track records in healthcare investing and deep operating experience in the Middle East and Southeast Asia. For more information visit: TVMCapitalHealthcare.com 

For media inquiries, please contact:

DEBx Medical: Chandrita Jaisinghani, press@debx-medical.com, +31 85 0878096


source: DEBx Medical B.V.

【你點睇?】TikTok美國禁令生效前大批「TikTok難民」湧入小紅書,你認為該現象會否對中美文化交流帶來正面影響?特朗普暫緩禁令後小紅書熱潮會否持續?► 立即投票

人氣文章
最近7天
1
高息定存 | 6個月港元定存3.8厘新高,188日快閃優惠3.68厘
2
高息定存 | 富邦推快閃定存優惠3個月3.9厘,華僑188日3.68厘
3
專訪|林本利系列專訪逢周五登場,股市篇:勿驚美股調整,港股那些可以放心買那些勿沾手(有片)
4
高息定存 | 工銀亞洲推3個月5厘息搶新客,招商永隆推快閃優惠
5
高息定存 | 信銀國際上調1個月定存年息至高達3.88厘
6
回顧展望-新股復燃 | 政策市激發IPO 惟六成新股破發損行情
7
神州經脈 | 特別國債或發3萬億,滬指逼近三千四,日外相訪華
8
回顧展望-國際形勢 | 全球動盪戰火連天,特朗普時代重臨
9
高息定存 | 聖誕前夕銀行加存息吸資金,大眾3個月加至3.6厘
10
【FOCUS】「晶片戰」揮新大棒,技術制華恐適得其反
11
【FOCUS】零售寒冬襲京滬港,逆市奇葩值借鏡
12
今日焦點股 | 據報螞蟻集團重組架構,劉政或出任首席財務官
13
神州經脈 | 工業利潤降幅收窄,低空經濟發展司成立,滬指全周升
14
港股 | 蕭猷華:恒指料退守至18600點,宜逢低吸納
15
神州經脈 | 換手機可獲政府補貼,政策利率將降,滬指周挫逾5%
16
內銀股 | 人行再提擇機減息降準,內銀獲中金唱好,應該點部署?
17
神州經脈 | PMI遜預期,滬指全年止跌回升,人幣年度貶幅擴
18
回顧展望-國際金融 | 金融市場現重要轉折,戰亂刺激避險
19
回顧展望-息息相關 | 銀行股明年看好滙控,重組有利減低支出
20
新股掛牌 | 布魯可首日掛牌升41%,每手賺7395元
21
高息定存 | 一周高息合集,銀行年尾搶資金,大眾3個月3.6厘
22
大國博弈 | 【FOCUS】騰訊商湯寧德重挫,CMC清單劍指軍民融合
23
回顧展望-人幣走貶 | 關稅殺到,先貶為敬,人幣明年勢見7.5
24
高息定存 | 一周高息合集,恒生1個月定存4厘,工銀亞洲3個月最高5厘
25
回顧展望-A股自強 | 憧憬國策利好,機構對明年股市走勢樂觀
26
加州山火 | 【FOCUS】洛杉磯烈火焚城,天災背後藏人禍
27
港股 | 蕭猷華:恒指維持19700點至21000點上落
28
藍圖2.0 | 旅遊發展藍圖2.0提四大策略,推特色項目智慧旅遊並開拓客源
29
高息定存 | 渣打特選客6個月3.48厘,建行亞洲推1個月6.18厘高息吸客
30
港股 | 蕭猷華:恒指春節前可挑戰21500點
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

【etnet 30周年】多重慶祝活動一浪接一浪,好禮連環賞!

【蛇年行大運 新年好賞「飾」】etnet賞太歲開運飾物

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

貨幣攻略

大國博弈

說說心理話

聖誕新年特輯

Watch Trends 2024

北上食買玩

Art Month 2024

秋天養生食療

山今養生智慧

輕鬆護老